Leerink Partnrs Has Bullish Estimate for RXRX Q2 Earnings

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) - Equities researchers at Leerink Partnrs lifted their Q2 2025 EPS estimates for Recursion Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 6th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($0.34) per share for the quarter, up from their previous estimate of ($0.40). The consensus estimate for Recursion Pharmaceuticals' current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals' Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.92) EPS and FY2027 earnings at ($0.47) EPS.

Several other equities analysts have also recently weighed in on the stock. Needham & Company LLC decreased their target price on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday. Leerink Partners lowered their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research note on Friday, February 28th. Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. KeyCorp lowered their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Finally, Morgan Stanley reduced their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $7.60.

Recursion Pharmaceuticals Stock Up 0.8 %

RXRX stock opened at $4.20 on Thursday. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -2.74 and a beta of 0.99. Recursion Pharmaceuticals has a twelve month low of $3.79 and a twelve month high of $12.36. The business has a 50 day moving average price of $5.62 and a two-hundred day moving average price of $6.69. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The business had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. During the same quarter in the prior year, the company earned ($0.39) earnings per share. The company's quarterly revenue was up 7.2% on a year-over-year basis.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently modified their holdings of RXRX. ARK Investment Management LLC raised its stake in Recursion Pharmaceuticals by 7.6% in the 1st quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company's stock worth $184,174,000 after purchasing an additional 2,469,104 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Recursion Pharmaceuticals by 40.1% during the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after purchasing an additional 9,737,196 shares during the period. Softbank Group CORP. acquired a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $99,152,000. Kinnevik AB publ boosted its stake in shares of Recursion Pharmaceuticals by 12.8% in the first quarter. Kinnevik AB publ now owns 13,434,171 shares of the company's stock valued at $71,067,000 after buying an additional 1,528,503 shares during the period. Finally, Novo Holdings A S acquired a new stake in Recursion Pharmaceuticals during the fourth quarter worth approximately $68,375,000. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.